Similar articles

• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Barnett AH, et al. N Engl J Med. 2004 Nov 4;351(19):1952-61. doi: 10.1056/NEJMoa042274. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516696 Clinical Trial.
• [In the DETAIL. Kidney protection in manifestations of microalbuminuria].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2006 Jun 29;148(26):51. MMW Fortschr Med. 2006. PMID: 16875382 German. No abstract available.
• Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.

  Barnett AH. Barnett AH. Acta Diabetol. 2005 Apr;42 Suppl 1:S42-9. doi: 10.1007/s00592-005-0180-4. Acta Diabetol. 2005. PMID: 15868119 Review.
• Prevention of loss of renal function over time in patients with diabetic nephropathy.

  Barnett A. Barnett A. Am J Med. 2006 May;119(5 Suppl 1):S40-7. doi: 10.1016/j.amjmed.2006.01.013. Am J Med. 2006. PMID: 16563947 Review.
• [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].

  Nitschmann S, Girndt M, Köhler H. Nitschmann S, et al. Internist (Berl). 2005 Aug;46(8):923-4, 926. doi: 10.1007/s00108-005-1466-x. Internist (Berl). 2005. PMID: 15990988 German. No abstract available.